Grace Therapeutics, Inc. (GRCE) Stock Analysis

Grace Therapeutics, Inc. (GRCE) is a publicly traded company in the HEALTHCARE sector. It trades at $2.50, carries a market capitalization of $41.63M. This page summarizes the public market data, fundamentals, and frequently asked questions for GRCE, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

• Price: $2.50
• Market Cap: $41.63M
• EPS: $-0.31
• 52-Week High: $5.18
• 52-Week Low: $1.79

Market Sentiment

Grace Therapeutics, Inc. currently has a Neutral sentiment score of 0.02.

About Grace Therapeutics, Inc.

Grace Therapeutics, Inc., headquartered in Princeton, New Jersey, is a forward-thinking pharmaceutical company dedicated to the development of innovative therapies specifically for rare and orphan diseases. By harnessing advanced research methodologies and deep clinical expertise, the company is focused on addressing critical unmet medical needs in Canada and beyond. With a robust pipeline of specialized products, Grace Therapeutics positions itself strategically within the rare disease thera...

GNG Research Analysis

GNG Research scores Grace Therapeutics, Inc. (GRCE) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for GRCE.

Frequently Asked Questions

Does GRCE pay dividends?

Grace Therapeutics, Inc. (GRCE) does not currently pay a regular dividend.

What is GRCE's market cap?

Grace Therapeutics, Inc. (GRCE) has a market capitalization of $41.63M with a current stock price of $2.50.